Last reviewed · How we verify
new antiviral therapy
At a glance
| Generic name | new antiviral therapy |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation (PHASE1)
- Study of GS-3242 in Participants With HIV-1; Substudy-05 (PHASE1)
- Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (PHASE2)
- AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
- Study of GS-1219 in Participants With HIV-1 (PHASE1)
- Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B (PHASE1)
- Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders. (PHASE1, PHASE2)
- Study of Novel Antiretrovirals in Participants With HIV-1 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- new antiviral therapy CI brief — competitive landscape report
- new antiviral therapy updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI